Equity Profile
Post-Earnings Recap
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.65 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.65 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed caution regarding the financial outlook. They emphasized the importance of their ongoing projects and research.
Management did not provide specific revenue figures or guidance for the upcoming quarters.
The focus remains on advancing their pipeline despite the current financial results.
Immunome Inc's earnings report showed a loss per share of $0.65, with no revenue figures disclosed. The stock reacted negatively, declining by 1.93%. The lack of guidance and specific revenue details may have contributed to investor uncertainty.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
IDEAYA BIOSCIENCES I